- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03611322
A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)
January 7, 2020 updated by: Novo Nordisk A/S
A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector
This study compares semaglutide in two different injection tools called "PDS290" and "DV3372".
The study aims to show similar levels of semaglutide in the blood when using either of the two injection tools.
The researchers also want to look at how well the injection tools work.
Participants will either receive semaglutide using the PDS290 or the DV3372 injection tool.
This is decided by chance, like flipping a coin.
This is called randomisation.
Semaglutide is an approved medicine (thus available on the market) for people with type 2 diabetes.
Semaglutide will be injected subcutaneously (injection under the skin).
Participants will get a total of 5 injections with semaglutide.
The study will last for a maximum of 86 days.
Participants will have 17 scheduled site visits with the study physician or study staff at the study centre.
For one of the visits participants will stay at the research unit for 4 days and 3 nights.
Participants cannot take part in this study if participants have any disorder that the doctor thinks is a health problem.
Only healthy men and women are allowed to take part.
Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria: - Male or female, aged 18 to 55 years (both inclusive) at the time of signing informed consent.
- Body mass index between 20.0 and 29.9 kg/m^2 (both inclusive) and weight between 55.0 and 90.0 kg (both inclusive).
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using highly effective contraceptive methods.
- Any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol.
- Use of prescription medicinal products or non-prescription drugs or herbal products, except routine vitamins, topical medication, highly effective contraceptives and occasional use of paracetamol (not allowed within 24 hours before screening), within 14 days prior to the day of screening.
- Abuse or intake of alcohol, defined as any of the below: 1) Known or suspected alcohol abuse within 1 year prior to the day of screening (defined as regular intake of more than an average intake of 24 g alcohol daily for men and 12 g alcohol daily for women -12 g of alcohol equals about 300 mL of beer or lager, 100 mL of wine, or 25 mL spirits) or 2) Positive alcohol test at screening.
- Abuse or intake of drugs, defined as any of the below: 1) Known or suspected drug/chemical substance abuse within 1 year prior to the day of screening or 2) Positive drug of abuse test at screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DV3372 device
Participants will receive semaglutide on day 1, 8, 15, 22 and 29.
The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
|
Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
Semaglutide will be administered s.c.
(under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
Semaglutide will be administered s.c.
(under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
DV3372 device will be used for administration of semaglutide
|
Active Comparator: PDS290 semaglutide pen-injector
Participants will receive semaglutide on day 1, 8, 15, 22 and 29.
The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
|
Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
Semaglutide will be administered s.c.
(under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
Semaglutide will be administered s.c.
(under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
PDS290 pen-injector will be used for administration of semaglutide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-last,sema,Week5: the area under the plasma semaglutide concentration-time curve from 0 until last quantifiable measurement after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period
Time Frame: 0-840 hours (5 weeks)
|
Measured in nmol*h/L
|
0-840 hours (5 weeks)
|
Cmax,sema,Week5: the maximum plasma semaglutide concentration after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period
Time Frame: 0-840 hours (5 weeks)
|
Measured in nmol/L
|
0-840 hours (5 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
tmax,sema,Week5: time to Cmax of semaglutide after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period
Time Frame: 0-840 hours (5 weeks)
|
Measured in hours
|
0-840 hours (5 weeks)
|
t½,sema,Week5: terminal elimination half-life of semaglutide after first maintenance dose of subcutaneous semaglutide 1 mg administration following a four week escalation period
Time Frame: 0-840 hours (5 weeks)
|
Measured in hours
|
0-840 hours (5 weeks)
|
Number of site-initiated technical complaints with or without co-reported adverse events
Time Frame: from first semaglutide dose (day 1) and until the follow-up visit (5 weeks after the last dose of semaglutide)
|
Number of technical complaints
|
from first semaglutide dose (day 1) and until the follow-up visit (5 weeks after the last dose of semaglutide)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 8, 2018
Primary Completion (Actual)
January 7, 2019
Study Completion (Actual)
January 7, 2019
Study Registration Dates
First Submitted
July 26, 2018
First Submitted That Met QC Criteria
July 26, 2018
First Posted (Actual)
August 2, 2018
Study Record Updates
Last Update Posted (Actual)
January 9, 2020
Last Update Submitted That Met QC Criteria
January 7, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9535-4429
- U1111-1206-9372 (Other Identifier: World Health Organization (WHO))
- 2017-005127-25 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Semaglutide, 0.25 mg
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesitySpain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
-
Novo Nordisk A/SCompletedObesityKorea, Republic of, Thailand
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedOverweight and ObesityJapan, Korea, Republic of
-
Andrew J. Armstrong, MDCompletedProstate CancerUnited States